Patients with developmental delay or intellectual disability (DD/ID), autism spectrum disorders (ASD), and congenital anomalies (CA) account for the largest proportion of cytogenetic testing due to their high prevalence in the population. More than 80% of the chromosomal aberrations found in ID/DD or ASD are submicroscopic and not detected by classical cytogenetic methods. Chromosomal microarray (CMA) is used as the first test to detect copy number variations (CNVs) that are major cause of these disorders. Large cohort studies of patients with DD/ID, CA, or ASD screened by microarray found a diagnostic yield of 14-20% compared with ~ 3% for the standard G-banded karyotype (1, 2) .
The resolution level of the CMA has no limit, ie, it depends on the size and distance between the test probes on the array. Today, there are a number of commercially available array platforms, which differ in genome coverage, resolution, and application. A higher array resolution can mean not only an increased yield of clinical genetic diagnosis, but also a higher level of detection of benign CNVs or variants of unknown clinical significance (VOUS). Therefore, the correct choice of the resolution array platform that balances sensitivity and specificity is very important for clinical practice.
Defining the pathogenicity of CNVs is the major difficulty in the interpretation of the array results. The usual criteria used in the interpretation of the clinical relevance of a CNV are inheritance, size, type, and gene content.
In this study, we present the CMA analysis of 337 patients with DD/ID with or without dysmorphic features, ASD and/ or CA. In 30 patients, chromosomal imbalances had been previously detected by classical cytogenetic and molecular cytogenetic methods. These patients were analyzed by CMA to define more precisely the breakpoints and the gene content of the rearrangements and to clarify if there were any additional CNVs. The aim of the study was to determine the diagnostic yield of the CMA analysis on the remaining 307 patients and criteria that could help in classification and interpretation of the CNVs detected.
PAtIentS And MethodS

Patients
The analysis included 337 unrelated patients from Croatia, referred to the Department of Medical Genetics and Re- CNVs were categorized as pathogenic, benign and VOUS based on well-established microdeletion or microduplication regions, inheritance pattern, gene content, and size as described elsewhere (1, 3) . The term VOUS was used when variants were less than 300 kb and when or if they included genes of unknown clinical significance and when family studies were inconclusive or unavailable.
ReSultS
In 73 patients, clinically relevant variants in the genome were detected and better characterized; there were 61 microdeletions and 30 microduplications (Table 1) . In 19 patients, multiple imbalances were found ( Table 2) . Most of the pathogenic CNVs (68/91) were >1 Mb. VOUS were discovered in 35 patients: 25 had one VOUS, seven had two VOUS, and three subjects had one pathogenic CNV and one VOUS (subjects No. 49, 22, and 70). There were 17 microdeletions and 25 microduplications (Table 3) . Only seven of these 42 microdeletions and microduplications were >1Mb.
In the ID/DD, ASD, CA with/without dysmorphism group, there were only two patients with pathogenic CNVs. In the ID/DD, CA with/without dysmorphism group, there were 47 subjects with pathogenic CNVs and nine with VOUS. In the ID/DD, ASD with or without dysmorphism group, five patients had pathogenic CNVs and six had VOUS. In the ID/DD, with or without dysmorphism group, there were 14 patients with pathogenic CNVs and 11 with VOUS. There were five patients with pathogenic CNVs and four with VOUS in the CA with/without dysmorphism group, and only two patients with VOUS in the ASD with/without dysmorphism group.
The distribution of 51 newly diagnosed pathogenic CNVs and 42 VOUS by size showed that there were no VOUS grater than 5 Mb ( Genomic regions that were the most commonly affected by pathogenic CNVs were 8p23 (6 patients), 15q11.2 (6 patients), and 22q11.21 (5 patients). In the group with complex rearrangement, the most affected, relatively large region was 18q22.1q23 (5 patients).
Parents of 44 probands with pathogenic CNV or VOUS were available for DNA testing. Four VOUS were de novo and 16 were inherited. In eight cases, pathogenic CNVs were inherited from parents with balanced translocations, in seven cases one of the parent had same patho- dISCuSSIon Pathogenic CNV were found in 43 of total 307 patients previously not tested by other cytogenetic or molecular methods or in whom these tests were negative for genomic imbalances, representing an overall diagnostic yield of 14%. Our results are in accordance with other studies on genome-wide oligonucleotide arrays (1, 4, 5) . The diagnostic yield is known to correlate with the array resolution and the genomic coverage of the array used. Currently, we are using 8x60K array with 60 kb overall median probe spacing (higher in ISCA regions), and the results of this study showed that this platform is suitable for genetic testing of children with developmental disorders.
The microdeletion syndromes that were identified in more than one individual were: 15q11. VOUS were reported in 35 of 307 cases, including three cases with additional pathogenic CNV. The sizes of the VOUS varied from 2387 kb to 5 kb. The largest VOUS was duplication in the 1q21.2 region inherited from the apparently healthy father. The duplication involved only one pathogenic gene (GJA8) and partly affected the region causing 1q21.1 duplication syndrome (#612475 MIM). It is considered that a critical region causing 1q21.1 duplication syndrome is 800 kb in size (chr1: 146577487-147394506 GRCh37/ hg19) and includes at least 7 genes (6). Duplication in our patient overlapped only in 13 kb, and included only GJA8 gene associated with cataract not present in the patient. Hence, although the duplication was relatively large, it was classified as VOUS based on the gene content and the fact that it was inherited from the apparently healthy father. The smallest CNVs on X chromosome detected in three male patients were inherited from the normal heterozygous mother in patients No.s 12 and 84.
The most common size category of VOUS was <300 kb (40.5%). Based on the clinical presentation of our patients, *Abbreviations: ISCn -International System for human Cytogenetic nomenclature; kb -kilobases; Id/dd -intellectual disability/developmental delay; ASd -autism spectrum disorders; CA -congenital anomalies; M -male; F -female; dn -de novo; mat -maternally inherited; pat -paternally inherited. †In the ISCn report, monosomy/deletion/one copy is designated with x1, trisomy/duplication/three copy is designated with x3 in the genome, with x0 deletion on X chromosome in a male subject, and with x2 duplication on X chromosome in a male subject. the results are according to uCSC human Genome build 19 (national Center for Biotechnology Information build 37).
family studies, type of CNV (deletion vs duplication), gene content, and the size distribution of pathogenic CNVs and VOUS, we recommend using a 300 kb as an arbitrary cut off for clinically relevant CNV when using this platform.
The inheritance pattern of a CNV, when accompanied by clinical and family history information, can be useful. (7). The phenotypic features that are associated with dup 6p25.2p24.2 that were present in our patient were tall stature, dysmorphia, obesity, frequent respiratory infections, foot malformations, hypoplastic left kidney, hypospadias, and urethral stenosis. His 37-year old mother was dysmorphic, obese like her son, but had no associated anomalies. In addition, she suffered from osteopetrosis and polyarthralgia, which are presumably of different etiology. Despite the large duplications, both had completely normal intellectual functioning.
The CNVs that contain many genes or known disease genes are more likely to be pathogenic than those that contain few genes or genes of uncertain function. Thus, large CNVs are more likely than small CNVs to cause clinical manifestations as they generally encompass more genes, with a higher probability to affect a dosage-sensitive one. As deletions result in haploinsufficiency, some very small deletions, for example 61 kb deletion in 2p16.3 region altering NRXN1 gene (patients No. 8 and 2), can also be pathogenic (8) . Duplications are more difficult to interpret because some relatively large duplications have no pathogenic effect and are found in normal subjects. CNVs within regulatory regions of clinically relevant genes make interpretation even more complex. The major difference between patients with pathogenic CNVs and patients with VOUS was present in groups with ID/DD, ASD, CA with/without dysmorphism; ID/DD, CA with/without dysmorphism; and ASD with/without dysmorphism. This was expected, considering the size and number of pathogenic genes encompassed by pathogenic CNVs. ASD with/without dysmorphism was present in seven patients with pathogenic CNVs only in combination with ID/ DD and/or CA and in the VOUS group, it was twice as frequent as in the group with pathogenic CNVs. Subsets of individuals with ASD are more likely to carry disruptive de novo and rare CNVs and sequence-level mutations (10) . Microarray testing identifies etiology of ASD in 8%- In summary, our results showed that Agilent ISCA v2 Human Genome 8x60 K oligonucleotide microarray format provided reasonable resolution for clinical use, particularly in the ISCA regions containing known disease genes associated with well-established phenotypes. The CMA method revised the MLPA and conventional karyotyping results and provided a new, more detailed insight into genomic changes. It is to be expected that increasing number of smaller pathogenic CNVs will be discovered because there is a tendency for an increasing number of laboratories to use CMA platforms of higher resolution. This will simultaneously lead to an increased number of VOUS and the need to include other criteria for establishing their significance, based on data collection on new patients, genotype-phenotype correlation, and better understanding of the complex interaction of the genes included in the CNVs with the entire genome.
